The cyclosporine plus everolimus regimen showed a significantly better result with less efficacy failure ( compared with cyclosporine plus MMF : 3 % vs 25 % ) and better 1-year survival compared with tacrolimus plus MMF : 96.7 % vs 81.0 % .
